Pediatric cancers: 100,000 children treated as part of the My Child Matters program

Download the PDF version

Target achieved one year ahead of schedule

Five new projects in low-income countries

The Sanofi Espoir Foundation announced today that it has reached its goal of 100,000 children under care as part of the My Child Matters program to fight pediatric cancers. Initially set for the end of 2021, this goal was reached in November 2020, more than a year ahead of schedule. As part of its roadmap for the 2019-2021 period, the Foundation will also step up its projects by providing expertise and financial support for five new initiatives dedicated to children with cancer.

"The intense mobilization of all stakeholders, particularly health professionals in the field, has enabled us to meet our goals, even though we are only two-thirds of the way through the Foundation's three-year mandate," explains François Desbrandes, head of the My Child Matters program. "The drive to improve care for children with cancer continues with five new projects in low-income countries to be completed by the end of 2021.” 

The five projects selected factor in both the feasibility and potential impact of the proposed actions. These fall into four categories: early diagnosis (two projects), palliative care and pain control, access to care, and the fight against treatment abandonment. Four of the selected projects are in Africa and one in Asia. As a result of the My Child Matters program, the Sanofi Espoir Foundation is also helping boost the number of trained healthcare professionals, with more than 30,000 beneficiaries to date. Fifteen years after its creation, the My Child Matters program has already supported around 80 projects in some 60 countries.

About the My Child Matters program

The My Child Matters program acts as a catalyst in caring for children with cancer in developing countries. It provides financial support and expertise to ensure that all children have access to diagnosis and treatment.



This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies.